The results from our meta-analysis showed that the utility of BAP1 as a marker in the diagnosis of MM harbored a pooled sensitivity of 0.56 at a specificity of 1.00, meaning that loss of BAP1 immunostaining almost could rule in MM, but ruling BAP1 out as a marker seems to be premature. The gene discussed is BAP1; the disease is Miyoshi myopathy.